Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1Phase 1 1

Status

Completed 3Active not recruiting 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Other hematologic neoplasm 3Myeloid 3

Conditions

Leukemia, Myeloid, Acute 10Myelodysplastic Syndromes 7Leukemia, Myelomonocytic, Chronic 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Neoplasms 2Multiple Myeloma 2Lymphoma 2Advanced Solid Neoplasm 2Solid Tumors 1Renal Insufficiency 1Neoplasm, Residual 1Melanoma 1Liver Diseases 1Hodgkin Disease 1Hematologic Neoplasms 1Central Nervous System Neoplasms 1Advanced Solid Tumors 1Advanced Nonhematologic Malignancies 1

Interventions

fludarabine phosphate 52Cyclophosphamide 45Peripheral Blood Stem Cell Transplantation 42Busulfan 37Azacitidine 34Whole-Body Irradiation 31Mycophenolic Acid 29Cytarabine 28Cyclosporine 28Tacrolimus 27Methotrexate 25Filgrastim 21Decitabine 20Radiotherapy 19Antilymphocyte Serum 19Methylprednisolone 14Melphalan 13Etoposide 13fludarabine 10Cyclosporins 9Idarubicin 8Granulocyte Colony-Stimulating Factor 8Flow Cytometry 8sargramostim 7Psychiatric Rehabilitation 7Cord Blood Stem Cell Transplantation 7merphos 6aldesleukin 6Topotecan 6Therapeutics 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Completed × Leukemia, Myelomonocytic, Chronic × pevonedistat × Clear all
NCT03268954 2025-10-29

PANTHER

Takeda

Phase 3 Completed
454 enrolled 41 charts
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT03814005 2024-09-05

A Study of Pevonedistat in People With Blood Cancers or Solid Tumors With Kidney or Liver Problems

Takeda

Phase 1 Completed
17 enrolled 33 charts
MyeloidOther hematologic neoplasm

Liver Diseases, Myelodysplastic Syndromes, Neoplasms, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Renal Insufficiency

NCT02610777 2022-09-19

An Efficacy and Safety Study of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine in Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML) and Low-Blast Acute Myelogenous Leukemia (AML)

Takeda

Phase 2 Completed
120 enrolled 39 charts
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡